newsfilter
← Latest News
ClinicalTrials.gov·

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma - NCT04698187

Determine confirmed objective response (ORR) with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma, Evaluate the safety and tolerability of CMP-001 administered by IT injection in combination with nivolumab, Duration of response (DOR), (and 11 more...)